Exabis Library
Welcome to the e-CCO Library!
DOP007: Interleukin-10 inhibits human IFNγ and IL-17-producing T helper cells indirectly by controlling antigen-presenting cell function
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP008: Dietary manipulation of the healthy human and colitic murine gut microbiome by CD-TREAT diet and exclusive enteral nutrition; a proof of concept study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP008: Human intestinal Vδ2+ T-cells acquire antigen-presenting potency upon exposure to microbial phosphoantigen: modulation by mucosal inflammation and vedolizumab therapy
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP008: Safety of adalimumab in children and adolescents with moderate-to-severe Crohn’s disease: interim results of the CAPE registry
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP009: An autoimmunity-associated variant in PTPN22 protects from disease onset in mouse models of colitis
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP009: Choice of corticosteroids or exclusive enteral nutrition as the first induction of remission therapy does not affect disease behavior within two years of diagnosis
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP009: Comparative safety profile of vedolizumab and tumour necrosis factor–antagonist therapy for inflammatory bowel disease: a multicentre consortium propensity score-matched analysis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP01 Exclusive enteral nutrition for the treatment of adult Crohn’s disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
Tuesday, 4 August 2020, 1:21 PM by Dauren Ramankulov
DOP010: Activating PIK3CD mutations cause severe intestinal lymphonodular hyperplasia and an IBD-like phenotype
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP010: ECCO topical review on transitional care in inflammatory bowel disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP010: Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from a Central European nationwide cohort
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP011: Early immunomodulator exposure and the long-term outcome of Crohn’s disease: target for changing the natural history
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP011: Genotype–phenotype association analysis of inflammatory bowel disease in 6395 East Asian subjects: results from the international IBD Genetics Consortium
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP011: Risk of opportunistic infection in healthcare personnel with inflammatory bowel disease: a case-control study of the GETAID
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP012: Disease demarcation in ulcerative colitis is associated with different patterns of gene expression
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP012: Do ulcerative colitis patients treated with corticosteroids at diagnosis really have a more aggressive disease course?
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP012: Impact on clinical practice of Epstein-Barr virus infection in patients with inflammatory bowel disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP013: A 104 week mucosal healing assessment of symptomatic small bowel Crohn’s disease
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP013: An IBD-associated variant in PTPN2 promotes inflammatory responses but enhances the anti-inflammatory effect of spermidine
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP013: Definition of therapeutic response criteria using MRI in Crohn's disease patients treated with anti-TNF therapy: a multicenter prospective study (the IRMA study)
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM